Regulatory Approvals

FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC

By

Regulatory Approvals — FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC  Oncodaily

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. July 23, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Zidesamtinib (Jideytro) for ROS1-Positive Non-Small Cell Lung Cancer

Regulatory Approvals

With FDA approval, Celcuity sees big future for its new breast cancer drug

Regulatory Approvals

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Financial News For All

Regulation

Boeing class action over MAX 9 blowout decertified by US appeals court

Regulation

Congress Aims to Overturn SCOTUS Ruling on Pesticide Liability

Regulation

SEC Announces Departure of Principal Deputy Director of Enforcement Sam Waldon

Regulation

EPA Finalizes Cleanup Plan to Address Contamination on Properties at the Former Kil-Tone Co. Superfund Site Floodplain in Vineland, New Jersey